NCT00577512 · ADVERSE EVENTS

Adverse events

2006-32 Phase II Study of Rapidly Recycled High Dose DTPACE · Source last updated 2017-11-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Adverse events occurred during the study; they are not necessarily caused by treatment. Serious events are not interchangeable with severe/grade 3–4 events. These safety populations may differ from efficacy populations.

Collection time frame: Not reported
Other-event reporting threshold: 0%

Participants affected / participants at risk, as reported
Safety group	Serious events	Other events	Deaths
HD DTPACE 1. High dose DTPACE and stem cell collection if you do not already have sufficient stem cells stored 2. High dose DTPACE and stem cell re-infusion 3. VTD Maintenance therapy	3 / 4	0 / 4	Not reported / Not reported

Group identifiers: EG000: HD DTPACE

Serious adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

assessment Type
SYSTEMATIC_ASSESSMENT
organ System
General disorders
stats
group Id
EG000
num Affected
1
num At Risk
4
num Events
1
term
hypoxemia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
stats
group Id
EG000
num Affected
1
num At Risk
4
num Events
4
term
DVT
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
General disorders
stats
group Id
EG000
num Affected
1
num At Risk
4
num Events
1
term
cellulitis
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
General disorders
stats
group Id
EG000
num Affected
1
num At Risk
4
num Events
1
term
pneumonia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
General disorders
stats
group Id
EG000
num Affected
1
num At Risk
4
num Events
1
term
shortness of breath, cough, extreme weakness

Other reported adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

Complete source fields

event Groups

description
1. High dose DTPACE and stem cell collection if you do not already have sufficient stem cells stored 2. High dose DTPACE and stem cell re-infusion 3. VTD Maintenance therapy
id
EG000
other Num Affected
0
other Num At Risk
4
serious Num Affected
3
serious Num At Risk
4
title
HD DTPACE

frequency Threshold

serious Events

assessment Type
SYSTEMATIC_ASSESSMENT
organ System
General disorders
stats
group Id
EG000
num Affected
1
num At Risk
4
num Events
1
term
hypoxemia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
Blood and lymphatic system disorders
stats
group Id
EG000
num Affected
1
num At Risk
4
num Events
4
term
DVT
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
General disorders
stats
group Id
EG000
num Affected
1
num At Risk
4
num Events
1
term
cellulitis
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
General disorders
stats
group Id
EG000
num Affected
1
num At Risk
4
num Events
1
term
pneumonia
assessment Type
SYSTEMATIC_ASSESSMENT
organ System
General disorders
stats
group Id
EG000
num Affected
1
num At Risk
4
num Events
1
term
shortness of breath, cough, extreme weakness

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice